deltatrials
Completed PHASE4 NCT00502242

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus

Sponsor: Pfizer

Conditions Kidney Transplant
Interventions ramipril
Updated 7 times since 2017 Last updated: Aug 13, 2014 Started: Dec 31, 2007 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This PHASE4 trial investigates Kidney Transplant and is currently completed. Pfizer leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States, Boston, United States, Brisbane, Australia, Buenos Aires, Argentina, Buffalo, United States, Cape Town, South Africa, Capital Federal, Argentina, Charleston, United States, Chicago, United States, Cleveland, United States and 29 more location s